3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
50
Carcinoma, Non-Small-Cell Lung
36
Ovarian Neoplasms
35
Stomach Neoplasms
32
Esophageal Neoplasms
29
Uterine Cervical Neoplasms
21
Esophageal Squamous Cell Carcinoma
19
Fallopian Tube Neoplasms
16
Lung Neoplasms
13
Carcinoma, Ovarian Epithelial
13
Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma, Squamous Cell
9
Triple Negative Breast Neoplasms
8
Recurrence
8
Neoplasm Metastasis
6
Endometrial Neoplasms
6
Advanced Gastric Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Pancreatic Neoplasms
5
Nasopharyngeal Neoplasms
5
Hypopharyngeal Neoplasms
4
Oropharyngeal Neoplasms
3
Nasopharyngeal Carcinoma
3
Mouth Neoplasms
3
Melanoma
3
Laryngeal Neoplasms
3
Carcinoma
3
Anus Neoplasms
3
Adenocarcinoma Of Esophagus
3
Interventions
Paclitaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Advanced Non-squamous Non-small-cell Lung Cancer
×
Paclitaxel
×
Clear all
NCT04416035
2020-08-31
NSCLC
Zhejiang Teruisi Pharmaceutical Inc.
Phase 3
Unknown
608 enrolled